S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:OCUL - Ocular Therapeutix Stock Price, Forecast & News

$4.63
+0.03 (+0.65 %)
(As of 01/20/2020 03:15 PM ET)
Today's Range
$4.61
Now: $4.63
$4.77
50-Day Range
$3.88
MA: $4.22
$4.73
52-Week Range
$2.35
Now: $4.63
$5.55
Volume810,056 shs
Average Volume566,102 shs
Market Capitalization$222.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.99 million
Book Value$0.87 per share

Profitability

Net Income$-59,980,000.00
Net Margins-3,141.58%

Miscellaneous

Employees167
Market Cap$222.61 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.01. The biopharmaceutical company earned $0.83 million during the quarter, compared to analysts' expectations of $1.09 million. Ocular Therapeutix had a negative return on equity of 383.58% and a negative net margin of 3,141.58%. View Ocular Therapeutix's Earnings History.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ocular Therapeutix.

What price target have analysts set for OCUL?

6 Wall Street analysts have issued 1 year target prices for Ocular Therapeutix's stock. Their forecasts range from $3.00 to $24.00. On average, they anticipate Ocular Therapeutix's share price to reach $8.67 in the next twelve months. This suggests a possible upside of 87.2% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.

What is the consensus analysts' recommendation for Ocular Therapeutix?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.

Has Ocular Therapeutix been receiving favorable news coverage?

News coverage about OCUL stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ocular Therapeutix earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Ocular Therapeutix.

Who are some of Ocular Therapeutix's key competitors?

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Omeros (OMER), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Egalet (EGLT), Melinta Therapeutics (MLNT) and Canopy Growth (CGC).

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 52)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Michael H. Goldstein, Chief Medical Officer (Age 52)
  • Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 57)
  • Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 62)

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $4.63.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $222.61 million and generates $1.99 million in revenue each year. The biopharmaceutical company earns $-59,980,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe.View Additional Information About Ocular Therapeutix.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is http://www.ocutx.com/.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]


MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  575
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel